Analyst calls for calm after study links Novo Nordisk's bestsellers to sight loss

”It’s a small study and it’s not the first time smaller studies have signaled side effects,” he points out. 
Photo: Ricardo Rubio/AP/Ritzau Scanpix
Photo: Ricardo Rubio/AP/Ritzau Scanpix

The effect of a small study indicating an increased risk for users of the semaglutide products Ozempic and Wegovy for rare cases of vision loss should not drag Novo Nordisk’s share price down in the short term, Sydbank Senior Analyst Søren Løntoft Hansen tells Marketwire. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading